Predicting response after infliximab salvage in acute severe ulcerative colitis-Reference-Cited by-同舟云学术

Predicting response after infliximab salvage in acute severe ulcerative colitis

Published:2018-02-27 Issue:7 Volume:33 Page:1347-1352
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Choy Matthew C¹²³^ORCID,Seah Dean¹,Gorelik Alexandra⁴⁵,An Yoon-Kyo⁶,Chen Cheng-Yu⁶,Macrae Finlay A⁷,Sparrow Miles P⁸⁹,Connell William R²,Moore Gregory T⁹¹⁰,Radford-Smith Graham⁶,Van Langenberg Daniel R⁹¹¹^ORCID,De Cruz Peter¹³

Affiliation:

1. Department of Gastroenterology; Austin Health; Melbourne Australia

2. Department of Gastroenterology; St Vincent's Hospital; Melbourne Australia

3. Department of Medicine, Austin Academic Centre; University of Melbourne; Melbourne Australia

4. Institute for Health and Aging; Australian Catholic University; Melbourne Australia

5. Department of Medicine (RMH); University of Melbourne; Melbourne Australia

6. Department of Gastroenterology; Royal Brisbane and Women's Hospital; Brisbane Australia

7. Department of Colorectal Medicine and Genetics; Royal Melbourne Hospital; Melbourne Australia

8. Department of Gastroenterology; Alfred Health; Melbourne Australia

9. Faculty of Medicine, Nursing and Health Sciences; Monash University; Melbourne Australia

10. Department of Gastroenterology; Monash Health; Melbourne Australia

11. Department of Gastroenterology; Eastern Health; Melbourne Australia

Funder

University of Melbourne

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.14072/fullpdf

Reference22 articles.

1. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study;Kaplan;Am. J. Gastroenterol.,2012

2. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial;Laharie;Lancet,2012

3. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial;Williams;The Lancet Gastroenterology & Hepatology.,2016

4. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids;Narula;Am. J. Gastroenterol.,2016

5. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Outcome after Acute Severe Ulcerative Colitis: A Contemporary Review and Areas for Future Research;Journal of Clinical Medicine;2024-08-01

2. Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Systematic Review and Network Meta-analysis;Journal of Crohn's and Colitis;2024-07-09

3. Defining management strategies for acute severe ulcerative colitis using predictive models: a simulation-modeling study;Intestinal Research;2024-05-07

4. Predictors of adverse outcomes of steroids in patients with severe ulcerative colitis (systematic review and meta-analyses);Koloproktologia;2024-03-21

5. Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria;Journal of Gastroenterology;2024-01-26